A Case of a Potential Drug Interaction between Clobazam and Etravirine-Based Antiretroviral Therapy
Authors:
- 1 April 2011
- journal article
- case report
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (3) , 589-592
Abstract
The cytochrome P450 isoforms primarily involved in clobazam metabolism are CYP3A4 and 2C19. Drugs that modulate these enzymes would then be expected to alter the exposure of clobazam and its major metabolites. Etravirine, a second-generation non-nucleoside reverse transcriptase inhibitor has been shown to induce CYP3A4, while inhibiting CYP2C9 and CYP2C19. We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.Keywords
This publication has 17 references indexed in Scilit:
- Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepateLegal Medicine, 2010
- Suivi thérapeutique pharmacologique du clobazamTherapies, 2010
- Clinical Pharmacokinetics and Pharmacodynamics of EtravirineClinical Pharmacokinetics, 2009
- Pharmacokinetic Interaction Between Efavirenz and Carbamazepine After Multiple‐Dose Administration in Healthy SubjectsThe Journal of Clinical Pharmacology, 2008
- Induction Effects of Ritonavir: Implications for Drug InteractionsAnnals of Pharmacotherapy, 2008
- Proposal for a New Tool to Evaluate Drug Interaction CasesAnnals of Pharmacotherapy, 2007
- ClobazamNeurotherapeutics, 2007
- Contribution of CYP2C9, CYP2A6, and CYP2B6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP2C9*1/*1 GenotypeToxicological Sciences, 2006
- Clobazam in the Treatment of Epilepsy: A Review of the LiteratureEpilepsia, 1994
- Interactions Between Clobazam and Standard Antiepileptic Drugs in Patients with EpilepsyTherapeutic Drug Monitoring, 1992